Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Open Text Corporation (OTEX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Open Text Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Open Text Corporation trades at $22.63 (market cap $5.65B). The key difference: Open Text Corporation is the larger of the two by market cap, and Open Text Corporation pays a 4.72% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | OTEX | |
|---|---|---|
Market Cap | $4.49B | $5.65B |
Sector | Health | Technology |
52-Week High | $28.06 | $39.69 |
52-Week Low | $20.06 | $20.01 |
Enterprise Value | $3.69B | $10.81B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
OTEX trades at $22.57, down 2.04% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.95 and net income margin of 9.91%, supported by recent earnings beats. Recent news highlights strategic investments in AI and sovereign cloud in Europe, alongside a dividend payment scheduled for June 19, 2026.
The outlook is mixed; analyst consensus targets $29.75 (31.8% upside) with 42% buy ratings, but technical indicators suggest near-term pressure. Risks include execution of growth initiatives and market volatility. The stock presents a value opportunity if AI investments drive future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
